STUDY OBJECTIVES: It has been suggested that there might be a pathophysiological link and overlap between primary aldosteronism (PA) and obstructive sleep apnea (OSA). Therefore, in a prospective study, we evaluated the frequency of PA in hypertensive patients suspected of having OSA. METHODS: We included 207 consecutive hypertensive patients (mean age 53.2 ± 12.1 years, 133 M, 74 F) referred for polysomnography on the basis of one or more of the following clinical features: typical OSA symptoms, resistant or difficult-to-treat hypertension, diabetes, or cardiovascular disease. PA was diagnosed based on thew saline infusion test. RESULTS: Moderate-to-severe OSA was diagnosed in 94 patients (45.4% of the whole group). PA was diagnosed in 20 patients with OSA (21.3%) compared with 9 patients in the group without OSA (8.0%; P = .006). PA was also frequent in patients in whom symptoms of OSA were a sole indication for PA screening (15.4%) and in patients with and without resistant hypertension (24.5% and 17.8%, respectively). Most patients with PA and OSA were diagnosed with bilateral adrenal hyperplasia (18 patients, 90%). There were no major differences in clinical characteristics between patients with OSA with PA and those without PA. In multivariate models, moderate-to-severe OSA predicted the presence of PA (odds ratio 2.89, P = .018). CONCLUSIONS: Patients with clinically important moderate-to-severe OSA are characterized by a relatively high frequency of PA. Our results support the recommendations to screen patients with moderate-to-severe OSA for PA, regardless of the presence of other indications for PA screening.
STUDY OBJECTIVES: It has been suggested that there might be a pathophysiological link and overlap between primary aldosteronism (PA) and obstructive sleep apnea (OSA). Therefore, in a prospective study, we evaluated the frequency of PA in hypertensive patients suspected of having OSA. METHODS: We included 207 consecutive hypertensive patients (mean age 53.2 ± 12.1 years, 133 M, 74 F) referred for polysomnography on the basis of one or more of the following clinical features: typical OSA symptoms, resistant or difficult-to-treat hypertension, diabetes, or cardiovascular disease. PA was diagnosed based on thew saline infusion test. RESULTS: Moderate-to-severe OSA was diagnosed in 94 patients (45.4% of the whole group). PA was diagnosed in 20 patients with OSA (21.3%) compared with 9 patients in the group without OSA (8.0%; P = .006). PA was also frequent in patients in whom symptoms of OSA were a sole indication for PA screening (15.4%) and in patients with and without resistant hypertension (24.5% and 17.8%, respectively). Most patients with PA and OSA were diagnosed with bilateral adrenal hyperplasia (18 patients, 90%). There were no major differences in clinical characteristics between patients with OSA with PA and those without PA. In multivariate models, moderate-to-severe OSA predicted the presence of PA (odds ratio 2.89, P = .018). CONCLUSIONS: Patients with clinically important moderate-to-severe OSA are characterized by a relatively high frequency of PA. Our results support the recommendations to screen patients with moderate-to-severe OSA for PA, regardless of the presence of other indications for PA screening.
Authors: A Di Murro; L Petramala; D Cotesta; L Zinnamosca; E Crescenzi; C Marinelli; M Saponara; C Letizia Journal: J Renin Angiotensin Aldosterone Syst Date: 2010-05-20 Impact factor: 1.636
Authors: Brian C Ruhle; Michael G White; Salman Alsafran; Edwin L Kaplan; Peter Angelos; Raymon H Grogan Journal: Surgery Date: 2018-11-08 Impact factor: 3.982
Authors: Beata Krasińska; Angelika Miazga; Szczepan Cofta; Ludwina Szczepaniak-Chicheł; Tomasz Trafas; Zbigniew Krasiński; Katarzyna Pawlaczyk-Gabriel; Andrzej Tykarski Journal: Pol Arch Med Wewn Date: 2016-05-27
Authors: Denise M O'Driscoll; Shane A Landry; Jonathan Pham; Alan Young; Scott A Sands; Garun S Hamilton; Bradley A Edwards Journal: Sleep Date: 2019-10-21 Impact factor: 5.849
Authors: Oded Friedman; T Douglas Bradley; Christopher T Chan; Robert Parkes; Alexander G Logan Journal: Hypertension Date: 2010-11-08 Impact factor: 10.190
Authors: E Florczak; A Prejbisz; E Szwench-Pietrasz; P Sliwiński; P Bieleń; A Klisiewicz; I Michałowska; E Warchoł; M Januszewicz; M Kała; A Witkowski; A Więcek; K Narkiewicz; V K Somers; A Januszewicz Journal: J Hum Hypertens Date: 2013-05-23 Impact factor: 3.012
Authors: Yi Wang; Chuan Xiang Li; Ying Ni Lin; Li Yue Zhang; Shi Qi Li; Liu Zhang; Ya Ru Yan; Fang Ying Lu; Ning Li; Qing Yun Li Journal: Front Endocrinol (Lausanne) Date: 2022-01-12 Impact factor: 5.555
Authors: Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu Journal: Front Cardiovasc Med Date: 2022-02-02